Quincy Bioscience researches, develops and plans to market therapeutic compounds for the treatment of neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, stroke, Huntington’s disease, and Amyotrophic Lateral Sclerosis (ALS). New therapeutics will be based on the calcium-binding protein apoaequorin. Calcium-binding proteins are important in the protection of certain cellular populations and decrease over the course of aging or disease progression. In June 2004, the company applied for its first patent on the apoaequorin technology. Research and development work is conducted in university laboratories in addition to Quincy Bioscience's own facilities to fully develop the therapeutic applications of this technology. Apoaequorin acts in a protective manner similar to proteins that are depleted in humans with these diseases of aging. The dietary supplement Prevagen® has been developed based on Quincy Bioscience’s core technology and is now available nationwide in health food stores and Rite-Aid chain drug stores. Prevagen is marketed to assist in Brain Cell Protection. More information on the dietary supplement applications of Quincy Bioscience's technology can be found at www.prevagen.com.